bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

PUBLISHED ON December 6, 2021

December 6, 2021 (San Antonio, TX) bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how bioAffinity successfully uses RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), held virtually Dec. 6-11, 2021.

read more

Vice President of Research David Elzi, PhD, will present groundbreaking research at the American Society of Cell Biology Cell Bio Virtual, December 1 – 10, 2021

PUBLISHED ON September 29, 2021

Vice President of Research David Elzi, PhD, will present groundbreaking research leading to bioAffinity’s discovery of how silencing two cell receptors results in cancer cell toxicity, while normal cells are unaffected.  His presentation at the American Society of Cell Biology Cell Bio Virtual 2021 will be available December 1-10, 2021 for conference participants.  ASCB Cell Bio is the largest online forum for cell biologist around the world, bringing together a diverse global community of the brightest minds in cell biology.

read more

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

PUBLISHED ON September 23, 2021

September 23, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office issued a Notice of Acceptance for bioAffinity subsidiary OncoSelect’s patent protecting compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs.

read more

San Antonio-based bioAffinity Technologies’ first cancer test ready to hit the market

PUBLISHED ON September 16, 2021

San Antonio Business Journal (September 16, 2021) More than seven years after its launch, bioAffinity Technologies is on the cusp of commercializing its initial product, the CyPath® Lung cancer diagnostic test. Precision Pathology Services, which has licensed the San Antonio-based company’s technology, has completed its validation of the clinical performance of CyPath® Lung and is now preparing to take the non-invasive test to market.

read more